In vitro drug release, mechanical performance and stability testing of a custom silicone elastomer vaginal ring releasing dapivirine and levonorgestrel
© 2022 The Author(s)..
We have previously reported a multipurpose silicone elastomer vaginal ring providing sustained release of dapivirine (an antiretroviral) and levonorgestrel (a progestin) for HIV prevention and hormonal contraception. During initial development, issues arose due to reaction between the ethynyl group in the levonorgestrel molecule and the hydride-functionalised polydimethylsiloxane components in the silicone elastomer formulation. This unwanted reaction occurred both during and to a lesser extent after ring manufacture, impacting the curing process, the mechanical properties of the ring, and the in vitro release of levonorgestrel. Recently, we reported custom silicone elastomer grades that minimise this reaction. In this follow-on study, we describe the manufacture, in vitro drug release, mechanical, and pharmaceutical stability testing of ring formulations prepared from a custom silicone elastomer and containing 200 mg dapivirine and 80, 160, 240 or 320 mg levonorgestrel. The rings showed mechanical properties similar to marketed ring products, sustained in vitro release of both drugs over 30 days in quantities deemed clinically relevant, offered acceptable assay values, and provided good product stability over 15 weeks at 40 °C and 75% relative humidity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics: X - 4(2022) vom: 18. Dez., Seite 100112 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Murphy, Diarmaid J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
HIV microbicide |
|---|
| Anmerkungen: |
Date Revised 08.02.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ijpx.2022.100112 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336608845 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336608845 | ||
| 003 | DE-627 | ||
| 005 | 20231225232526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpx.2022.100112 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1121.xml |
| 035 | |a (DE-627)NLM336608845 | ||
| 035 | |a (NLM)35128382 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Murphy, Diarmaid J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro drug release, mechanical performance and stability testing of a custom silicone elastomer vaginal ring releasing dapivirine and levonorgestrel |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.02.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Author(s). | ||
| 520 | |a We have previously reported a multipurpose silicone elastomer vaginal ring providing sustained release of dapivirine (an antiretroviral) and levonorgestrel (a progestin) for HIV prevention and hormonal contraception. During initial development, issues arose due to reaction between the ethynyl group in the levonorgestrel molecule and the hydride-functionalised polydimethylsiloxane components in the silicone elastomer formulation. This unwanted reaction occurred both during and to a lesser extent after ring manufacture, impacting the curing process, the mechanical properties of the ring, and the in vitro release of levonorgestrel. Recently, we reported custom silicone elastomer grades that minimise this reaction. In this follow-on study, we describe the manufacture, in vitro drug release, mechanical, and pharmaceutical stability testing of ring formulations prepared from a custom silicone elastomer and containing 200 mg dapivirine and 80, 160, 240 or 320 mg levonorgestrel. The rings showed mechanical properties similar to marketed ring products, sustained in vitro release of both drugs over 30 days in quantities deemed clinically relevant, offered acceptable assay values, and provided good product stability over 15 weeks at 40 °C and 75% relative humidity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HIV microbicide | |
| 650 | 4 | |a Hormonal contraception | |
| 650 | 4 | |a In vitro drug release | |
| 650 | 4 | |a Mechanical properties | |
| 650 | 4 | |a Multipurpose prevention technology (MPT) | |
| 650 | 4 | |a Silicone elastomer | |
| 700 | 1 | |a Dallal Bashi, Yahya H |e verfasserin |4 aut | |
| 700 | 1 | |a McCoy, Clare F |e verfasserin |4 aut | |
| 700 | 1 | |a Boyd, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Leeanne |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, François |e verfasserin |4 aut | |
| 700 | 1 | |a McMullen, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Kleinbeck, Kyle |e verfasserin |4 aut | |
| 700 | 1 | |a Dangi, Bindi |e verfasserin |4 aut | |
| 700 | 1 | |a Spence, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Hansraj, Bashir |e verfasserin |4 aut | |
| 700 | 1 | |a Devlin, Bríd |e verfasserin |4 aut | |
| 700 | 1 | |a Malcolm, R Karl |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics: X |d 2019 |g 4(2022) vom: 18. Dez., Seite 100112 |w (DE-627)NLM301258015 |x 2590-1567 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2022 |g day:18 |g month:12 |g pages:100112 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpx.2022.100112 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2022 |b 18 |c 12 |h 100112 | ||